Literature DB >> 18247165

Characterization of the functional and growth properties of cell lines established from ileal and rectal carcinoid tumors.

Gail A Stilling1, Heyu Zhang, Katharina H Ruebel, Alexey A Leontovich, Long Jin, Yoshinori Tanizaki, Shuya Zhang, Lori A Erickson, Timothy Hobday, Ricardo V Lloyd.   

Abstract

Carcinoids of the intestine are the most common gastrointestinal carcinoid tumors. Therapeutic options to treat patients with these tumors are limited. There are very few ileal carcinoid cell lines available for in vitro studies to analyze new drugs that could be effective in treating patients with metastatic tumors. A replication defective recombinant adenovirus with an SV40 early T-antigen insert was used to infect two intestinal carcinoid tumors to create carcinoid cell lines. The cell lines were studied by cell culture, reverse transcription polymerase chain reaction, Western blotting, and immunohistochemistry. Both cell lines expressed SV40 large T antigen and receptors for TGFbeta1, TGFbeta2, EGFR, and somatostatin receptors. Treatment with TGFbeta1 led to growth inhibition and increased apoptosis in the cultured cells. Octreotide inhibited cell growth of both cell lines while stimulating apoptosis. Treatment of the HC45 cells with gefitinib also inhibited cell growth in a concentration-dependent manner. TGFbeta treatment stimulated chromogranin A expression while expression of two other granins, chromogranin B and 7B2, did not change significantly. RNA profiling of cells treated with TGFbeta1 showed increased expression of vitamin D3 receptor. This finding was validated by real-time quantitative polymerase chain reaction, Western blotting, and immunohistochemistry. These results indicate that these carcinoid cell lines can be used to study the proliferative and apoptotic mechanisms involved in intestinal carcinoid tumor growth regulation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18247165     DOI: 10.1007/s12022-007-9001-3

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   4.056


  34 in total

1.  Clinical and in vitro studies of imatinib in advanced carcinoid tumors.

Authors:  James C Yao; Jun X Zhang; Asif Rashid; Sai-Ching J Yeung; Janio Szklaruk; Kenneth Hess; Keping Xie; Lee Ellis; James L Abbruzzese; Jaffer A Ajani
Journal:  Clin Cancer Res       Date:  2007-01-01       Impact factor: 12.531

Review 2.  Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract.

Authors:  Otto Rorstad
Journal:  J Surg Oncol       Date:  2005-03-01       Impact factor: 3.454

3.  A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake.

Authors:  L Kölby; P Bernhardt; H Ahlman; B Wängberg; V Johanson; A Wigander; E Forssell-Aronsson; S Karlsson; B Ahrén; G Stenman; O Nilsson
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

4.  Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors.

Authors:  L Kölby; B Wängberg; H Ahlman; L E Tisell; M Fjälling; E Forssell-Aronsson; O Nilsson
Journal:  World J Surg       Date:  1998-07       Impact factor: 3.352

5.  Chromogranin A, an "on/off" switch controlling dense-core secretory granule biogenesis.

Authors:  T Kim; J H Tao-Cheng; L E Eiden; Y P Loh
Journal:  Cell       Date:  2001-08-24       Impact factor: 41.582

6.  Effects of DNA methylation on galectin-3 expression in pituitary tumors.

Authors:  Katharina H Ruebel; Long Jin; Xiang Qian; Bernd W Scheithauer; Kalman Kovacs; Nobuki Nakamura; Heyu Zhang; Avraham Raz; Ricardo V Lloyd
Journal:  Cancer Res       Date:  2005-02-15       Impact factor: 12.701

7.  Establishment and characterization of two new rectal neuroendocrine cell carcinoma cell lines.

Authors:  Y Takahashi; M Onda; N Tanaka; T Seya
Journal:  Digestion       Date:  2000       Impact factor: 3.216

8.  The functional characterization of normal and neoplastic human enterochromaffin cells.

Authors:  Irvin M Modlin; Mark Kidd; Roswitha Pfragner; Geeta N Eick; Manish C Champaneria
Journal:  J Clin Endocrinol Metab       Date:  2006-03-14       Impact factor: 5.958

Review 9.  Tumour biology of gastroenteropancreatic neuroendocrine tumours.

Authors:  Carsten Grötzinger
Journal:  Neuroendocrinology       Date:  2004       Impact factor: 4.914

Review 10.  The chromogranins: their roles in secretion from neuroendocrine cells and as markers for neuroendocrine neoplasia.

Authors:  Steven A Feldman; Lee E Eiden
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

View more
  9 in total

Review 1.  New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors.

Authors:  Ben Lawrence; Bjorn I Gustafsson; Mark Kidd; Irvin Modlin
Journal:  Gastroenterol Clin North Am       Date:  2010-09       Impact factor: 3.806

2.  QGP-1 cells release 5-HT via TRPA1 activation; a model of human enterochromaffin cells.

Authors:  Hitoshi Doihara; Katsura Nozawa; Ryosuke Kojima; Eri Kawabata-Shoda; Toshihide Yokoyama; Hiroyuki Ito
Journal:  Mol Cell Biochem       Date:  2009-06-09       Impact factor: 3.396

3.  An analysis of trends and growth factor receptor expression of GI carcinoid tumors.

Authors:  Kanika A Bowen; Scott R Silva; Jessica N Johnson; Hung Q Doan; Lindsey N Jackson; Pat Gulhati; Suimin Qiu; Taylor S Riall; B Mark Evers
Journal:  J Gastrointest Surg       Date:  2009-07-07       Impact factor: 3.452

4.  Global hypomethylation and promoter methylation in small intestinal neuroendocrine tumors: an in vivo and in vitro study.

Authors:  Omid Fotouhi; Maral Adel Fahmideh; Magnus Kjellman; Luqman Sulaiman; Anders Höög; Jan Zedenius; Jamileh Hashemi; Catharina Larsson
Journal:  Epigenetics       Date:  2014-04-24       Impact factor: 4.528

Review 5.  Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models.

Authors:  Kenta Kawasaki; Masayuki Fujii; Toshiro Sato
Journal:  Dis Model Mech       Date:  2018-02-26       Impact factor: 5.758

6.  Somatostatin Analogue Treatment Primarily Induce miRNA Expression Changes and Up-Regulates Growth Inhibitory miR-7 and miR-148a in Neuroendocrine Cells.

Authors:  Kristina B V Døssing; Christina Kjær; Jonas Vikeså; Tina Binderup; Ulrich Knigge; Michael D Culler; Andreas Kjær; Birgitte Federspiel; Lennart Friis-Hansen
Journal:  Genes (Basel)       Date:  2018-07-04       Impact factor: 4.096

7.  MicroRNA expression in ileal carcinoid tumors: downregulation of microRNA-133a with tumor progression.

Authors:  Katharina Ruebel; Alexey A Leontovich; Gail A Stilling; Shuya Zhang; Alberto Righi; Long Jin; Ricardo V Lloyd
Journal:  Mod Pathol       Date:  2009-12-25       Impact factor: 7.842

8.  New model for gastroenteropancreatic large-cell neuroendocrine carcinoma: establishment of two clinically relevant cell lines.

Authors:  Andreas Krieg; Sabrina Mersch; Inga Boeck; Levent Dizdar; Eberhard Weihe; Zena Hilal; Markus Krausch; Birte Möhlendick; Stefan A Topp; Roland P Piekorz; Wolfgang Huckenbeck; Nikolas H Stoecklein; Martin Anlauf; Wolfram T Knoefel
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

9.  Proteomics Suggests a Role for APC-Survivin in Response to Somatostatin Analog Treatment of Neuroendocrine Tumors.

Authors:  Omid Fotouhi; Hanna Kjellin; Catharina Larsson; Jamileh Hashemi; Jorge Barriuso; C Christofer Juhlin; Ming Lu; Anders Höög; Laura G Pastrián; Angela Lamarca; Victoria Heredia Soto; Jan Zedenius; Marta Mendiola; Janne Lehtiö; Magnus Kjellman
Journal:  J Clin Endocrinol Metab       Date:  2016-07-26       Impact factor: 5.958

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.